GeneMedix sets sights on Southeast Asia

Article Abstract:

GeneMedix is seeking to expand into the Southeast Asian marketplace as it becomes the first biotech firm to list its shares in Singapore. The firm, as part of the expansion plan, will introduce its first products into China. However, other generic makers are doubtful as to whether GeneMedix will be able to have a significant impact in the regional market due to strong local competition and overseas imports.

Marketing procedures, Southeast Asia, GeneMedix

---

Millennium and Aventis in unique pact

Article Abstract:

Millennium and Aventis Pharma form an alliance to develop and market antiinflammatory products, with Millennium taking half the profits in the United States while shouldering half the cost of creating new treatments.

Germany, Strategic alliances, Antiinflammatory Drugs, Millennium Pharmaceuticals Inc., MLNM, Anti-inflammatory agents, Aventis Pharma AG

---

Approval heralds new generation of kinase inhibitors?

Article Abstract:

Basel, Switzerland-based Novartis gained FDA approval in May 2001, for the first small-molecule kinase inhibitor for the treatment of myeloid leukemia.

Government regulation (cont), Switzerland, Anticancer Drugs, Brief Article, Novartis AG, Antineoplastic agents, NVTSY

Similar abstracts:

• Abstracts: Salvage job needed after takeover U-turn. Psion interest heralds end of Sugar's Amstrad. IT hardware
• Abstracts: A ubiquitin-based tagging system for controlled modulation of protein stability. Receptor-targeted optical imaging of tumors with near-infrared flurorescent ligands
• Abstracts: Germany gets a makeover. Could Germany lose triple-A rating? Germany: Hands across the rhine
• Abstracts: Right idea - but the wrong reasons. Doubts hamper old economy equities
• Abstracts: Shopkeepers' woes spur new profit pessimism. Investors to inherit Kingfisher rejects. A bumpy rise

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.